ACTIVITY OF CHIMERIC ANTIBODIES TO CD20 ON B LYMPHOCYTES IN PATIENT WITH SEVERE SYSTEMIC TYPE OF JUVENILE RHEUMATOID ARTHRITIS
Abstract
Key words: children, juvenile rheumatoid arthritis, rituximab.
About the Authors
E.I. AlexeevaRussian Federation
K.B. Isaeva
Russian Federation
T.M. Bzarova
Russian Federation
S.I. Valieva
Russian Federation
A.O. Lisitsin
Russian Federation
E.L. Semikina
Russian Federation
E.A. Kopyl'tsova
Russian Federation
References
1. Szer I.S., Kimura Y., Malleson P.N., Southwood T.R. Arthritis in children and adolescents. Juvenile Idiopathic Arthritis. Oxford: University Press. 2006. 456 p.
2. Cassidy J., Petty R., eds. Texbook of paediatric rheumatology, 5th Ed. Elsevier Saunders. 2005.
3. Бзарова Т.М, Алексеева Е.И., Петеркова В.А. Роль факторов болезни и факторов противоревматической терапии в развитии низкорослости у детей, страдающих ювенильным ревматоидным артритом. Вопросы современной педиатрии. 2006; 5 (5): 13–18.
4. Leandro M.J., Edwards J.C., Cambridge G: Clinical outcome in 22 patients with rheumatoid arthritis treated with B lymphocyte depletion. Ann. Rheum. Dis. 2002; 61: 883–888.
5. Leandro M.J., Edwards J.C., Cambridge G. et al. An open study of B lymphocyte depletion in systemic lupus erythematosus. Arthritis Rheum. 2002; 46: 2673–2677.
6. Oligino T.J., Dalrymple S.A. Targeting B cells for the treatment of rheumatoid arthritis. Arthritis Res. Ther. 2003; 5 (Suppl 4): 7–11.
7. Edwards J.C., Cambridge G., Abrahams V.M. Do self-perpetuating B lymphocytes drive human autoimmune disease? Immunology. 1999; 97: 188–196.
8. Gause A., Berek C. The role of B cells in the pathogenesis of rheumatoid arthritis: potential implications for treatment. Bio-Drugs. 2001; 15: 73–79.
9. Zhang Z., Bridges S.L. Jr. Pathogenesis of rheumatoid arthritis: role of B lymphocytes. Rheum. Dis. Clin. North Am 2001; 27: 335–353.
10. Насонов Е.Л. Новые направления терапии ревматоидного артрита: перспективы применения моноклональных антител к В–лимфоцитам (ритуксимаб). Русский медицинский журнал. 2006; 4 (25): 1–4.
11. Panayi G.S. B cell-directed therapy in rheumatoid arthritis clinical experience. J. Rheumatol. Suppl. 2005; 73: 19–24.
12. Edwards J.C.W., Cambridge G. Sustained improvement in rheumatoid arthritis following a protocol designed to deplete В lymphocytes. Rheumatology (Oxford). 2001; 40: 205—211.
13. De Vita S., Zaja F., Sacco S. et al. Efficacy of selective В cell blockade in the treatment of rheumatoid arthritis. Arthritis Rheum. 2002; 46: 2029–2033.
14. Kramrn H., Hansen K.E., Gowing E., Bridges A. Successful therapy of rheumatoid arthritis with rituximab. Renewed interest in the role of В ceils in the pathogenesis of rheumatoid arthritis. J. Clin. Rheumatol. 2004; 10: 28–32.
15. Kneitz C., Wilhelm M., Tony H.P. improvement of refractory rheumatoid arthritis after depletion of B cells. Scand J. Rheumatol. 2004; 33: 82–86.
16. Cambridge G., Leandro M.J., Edwards J.C. et al. Serologic changes following В lymphocyte depletion therapy for rheumatoid arthritis. Arthritis Rheum. 2003; 48: 2146–2154.
17. Pugh-Bernard A.E., Silverman G.J., Cappione A.J. et al.: Regulation of inherently autoreactive VH4-34 B cells in the maintenance of human B cell tolerance. J. Clin. Invest. 2001; 108: 1061–1070.
18. Edwards C.W., Szczepanski L., Szechinski J. et al. Efficacy of B–cell Targeted therapy with rituximab in patients with rheumatoid arthritis. New Engl. J. Med. 2005; 350: 2572–2581.
19. Насонов Е.Л. Перспективы применения моноклональных антител к В-лимфоцитам (ритуксимаб) при ревматоидном артрите. Клиническая фармакология и терапия. 2006; 1-5: 55–58.
20. Emery P., Fleishmann R., Filipowicz-Sospowska A. et al. The Efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment. Results of a phase lib randomized, double-blind, placebo-controlled dose-range trial. Arthritis Rheum. 2006; 54: 1390–1400.
21. Martini G., Zulian F. Juvenile idiopathic arthritis: current and future treatment option. Expert Opion. Pharmacother. 2006; 7 (4): 387–399.
22. Алексеева Е.И, Бзарова Т.М., Семикина Е.Л, Акулова С.С. Опыт применения ритуксимаба у больной с системным ювенильным ревматоидным артритом. Вопросы современной педиатрии. 2006; 5 (6): 96–100.
23. Алексеева Е.И., Литвицкий П.Ф. Ювенильный ревматоидный артрит. Этиология. Патогенез. Клиника. Алгоритмы диагностики и лечения. Руководство для врачей, преподавателей, научных сотрудников. Под ред. А.А. Баранова. М. 2007. С. 325–339.
24. Алексеева Е.И., Бзарова Т.М., Валиева С.И. и др. Ритуксимаб: новые возможности лечения тяжелого рефрактерного ювенильного артрита. Вопросы современной педиатрии. 2008; 7 (2): 22–30.
Review
For citations:
Alexeeva E., Isaeva K., Bzarova T., Valieva S., Lisitsin A., Semikina E., Kopyl'tsova E. ACTIVITY OF CHIMERIC ANTIBODIES TO CD20 ON B LYMPHOCYTES IN PATIENT WITH SEVERE SYSTEMIC TYPE OF JUVENILE RHEUMATOID ARTHRITIS. Current Pediatrics. 2008;7(4):136-142.
Email this article 
